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AbstractWhole-exome sequencing (WES) has been increasingly useful for the diagnosis of
patients with rare causes of anemia, particularly when there is an atypical clinical
presentation or targeted genotyping approaches are inconclusive. Here, we describe
a 20-yr-old man with a lifelong moderate-to-severe anemia with accompanying
splenomegaly who lacked a definitive diagnosis. After a thorough clinical workup and
targeted genetic sequencing, we identified a paternally inherited β-globin mutation
(HBB:c.93-21G>A, IVS-I-110:G>A), a known cause of β-thalassemia minor. As this
mutation alone was inconsistent with the severity of the anemia, we performed WES.
Although we could not identify any relevant pathogenic single-nucleotide variants (SNVs)
or small indels, copy-number variant (CNV) analyses revealed a likely triplication of the
entire α-globin cluster, which was subsequently confirmed by multiplex ligation-
dependent probe amplification. Treatment and follow-up was redefined according to the
diagnosis of β-thalassemia intermedia resulting from a single β-thalassemia mutation in
combination with an α-globin cluster triplication. Thus, we describe a case where the
typical WES-based analysis of SNVs and small indels was unrevealing, but WES-based
CNV analysis resulted in a definitive diagnosis that informed clinical decision-making.
More generally, this case illustrates the value of performing CNV analysis when WES is
otherwise unable to elucidate a clear genetic diagnosis.
[Supplemental material is available for this article.]
INTRODUCTION
Whole-exome sequencing (WES) has been remarkably successful at helping clinicians and
researchers identify pathogenic single-nucleotide variants (SNVs) or small indels that result
in severe disease (Sankaran et al. 2012, 2015; Sankaran and Gallagher 2013; Yang et al.
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2013; Lacy et al. 2016). In a smaller number of cases, rare copy-number variants (CNVs) that
are inferred from differences in WES read coverage have also been identified as pathogenic
variants (de Ligt et al. 2013; Poultney et al. 2013; Kelsen et al. 2015; Miyatake et al. 2015).
Typically, however, putative CNV calls are not a component of the clinical sequencing deliv-
erables. Indeed,WES-based CNV calls are generally of lower quality than whole-genome se-
quencing (WGS), microarray, or array comparative genomic hybridization-based calls
(Samarakoon et al. 2014; Belkadi et al. 2015), although these approaches have additional
cost when compared with WES-based CNV calling when WES data are already available.
β-Thalassemia intermedia is typically caused by mutations that affect copies of the β-
globin gene that limit, but do not completely abrogate, the production of functional β-globin
chains, resulting in a moderate anemia, often with iron overload and other comorbidities (for
review, see Vichinsky 2016). The presence of a heterozygous β-globin mutation concurrent
with a triplication of the α-globin gene have been described in a number of patients with
a clinical presentation ranging from thalassemia minor to intermedia (Kanavakis et al.
1983; Sampietro et al. 1983; Galanello et al. 1983; Thein et al. 1984; Henni et al. 1985;
Camaschella et al. 1987; Kulozik et al. 1987; Oron et al. 1994; Traeger-Synodinos et al.
1996; Bianco et al. 1997; Giordano et al. 2009; Farashi et al. 2015; Mehta et al. 2015;
Clark et al. 2016). In most cases, the genetic changes were αααanti3.7, the counterpart
of the α−3.7 deletion, the most common deletion of the α-globin locus, which spans 3.7 kb
and involves both the α2- and α1-globin genes. This genetic change is easily detectable
by restriction endonuclease mapping or multiplex Gap-PCR (Liu et al. 2000; de Mare et al.
2010). Here, we performed WES and searched for pathogenic variants in a 20-yr-old man
who was initially clinically diagnosed with a rare congenital form of anemia (congenital
dyserythropoietic anemia or CDA). Although we could not identify any pathogenic SNVs
or indels in the knownCDAgenes,WES-basedCNV analysis revealed an α-globin triplication
that was coinherited with a heterozygous β-globin mutation, resulting in a definitive diagno-
sis of β-thalassemia intermedia that impacted the ongoing clinical management of this
patient.
RESULTS
Clinical Presentation
At the age of 18, the patient was first referred to our hematology clinic at the Schneider
Children’s Medical Center of Israel for evaluation of a lifelong anemia. Medical records
showed that at 8 mo of age hemoglobin of 7 g/dl (normal: 10.5–14 g/dl) was noted, while
MCV was 62 fl (normal: 73–85 fl). Reticulocyte count was 4%, LDH and indirect bilirubin
were elevated, and iron status and thyroid function tests were normal. The father was
of Eastern-European origin and the mother was an Ashkenazi Jew. The parents were non-
consanguineous. Upon presentation to our clinic, a physical examination was performed.
The patient appeared jaundiced and his spleenwas palpated 12 cmbelow the costalmargin.
The patient also developed cholelithiasis. Hemoglobin levels ranged between 7 and 9 g/dl,
whereas theMCV ranged between 62 and 70 fl. A bonemarrow aspiration revealed erythroid
hyperplasia with mild dyserythropoiesis, a few binucleated erythroid precursors, and
some megaloblastic changes (Fig. 1). Iron staining revealed no evidence of sideroblastic
anemia. A thorough workup was performed to rule out enzymopathies, including glucose
6-phosphate dehydrogenase, pyruvate kinase, phosphofructokinase, glucosephosphate
isomerase, phosphoglycerate kinase, and aldolase deficiency. Membrane defects were
ruled out by the osmotic fragility test.
A molecular workup revealed that the patient was a carrier of the HBB:c.93-21G>A
(IVS-I-110:G>A) mutation in the β-globin gene (Young et al. 1985). The father was found to
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carry the same mutation, although he had not previously come to clinical attention for this
mild case of β-thalassemia minor. Therefore, the presence of one copy of the mutated allele
was unlikely to be sufficient to cause the severe lifelong anemia and morphological changes
observed and additional genetic causes were investigated. Sequencing and multiplex gap-
PCR of the α-globin gene did not reveal any abnormalities, including the α−3.7 deletion and
αααanti3.7 triplication (Liu et al. 2000; de Mare et al. 2010). Given the mild dyserythropoiesis,
the CDA genes (CDAN1, C15ORF41, SEC23B, KIF23, KLF1, and GATA1) were sequenced
but no pathogenic variants could be identified.
Genomic Analyses
Given the unrevealing results of the targeted genetic approaches, whole-exome sequencing
was performed on the patient (Supplemental Table 1). Forty-six candidate erythroid genes
were first investigated for rare (ExAC AF < 0.01%) and potentially damaging (loss-of-function
or missense) mutations, but no candidate variants for the anemia could be identified. Given
that our typical WES-based SNV and small indel analysis was also unrevealing, we decided to
call putative CNVs using WES read coverage. This analysis resulted in the identification of
eight putative CNVs (Table 1) that were present at a frequency of <5% in control samples.
Inspection of these rare putative CNVs revealed a possible triplication of the α-globin cluster
(Chr16:160473-240621), in addition to the known mutation in the β-globin gene (Fig. 2).
Although maternal DNA was not available to determine the exact inheritance pattern,
Figure 1. Bone marrow morphology of the patient demonstrating erythroid hyperplasia (A) and dyserythro-
poietic changes (B). Scale bar, 50 µM.
Table 1. Rare copy number variants identified in proband
Chromosome Start End Event No. of exons
1 92,251,714 92,433,879 Duplication 7
2 109,271,481 109,287,355 Deletion 4
5 177,171,344 177,210,906 Duplication 7
6 610,047 656,996 Deletion 7
7 100,606,688 100,610,365 Deletion 7
11 89,664,289 89,715,334 Duplication 9
16 160,473 240,621 Duplication 23
17 19,532,927 19,536,653 Deletion 4
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multiplex ligation-dependent probe amplification (MLPA) confirmed that the patient har-
bored a large triplication of the whole α-globin cluster including HBA1, HBA2, and HS40-
HBQ1-3 (Fig. 3). No other complete genes were present in this triplication event.
Importantly, this triplication was larger than would be detected with typical multiplex gap-
PCR approaches.
Treatment Outcomes
Thalassemia results from imbalance in the levels of α- and β-globin chains. In β-thalassemia,
the α/β globin ratio is increased, resulting in excess α-globin, which is toxic to red blood cell
precursors. Generally, β-thalassemia symptoms can be partially ameliorated by mutations
that reduce the overall synthesis of α-globin but worsened by mutations that result in excess
α-globin.
The combination of α-thalassemia triplications and heterozygous β-thalassemia muta-
tions are known to result in a clinical presentation of thalassemia intermedia (Galanello
et al. 1983; Thein et al. 1984; Henni et al. 1985; Camaschella et al. 1987; Kulozik et al.
1987; Oron et al. 1994, Traeger-Synodinos et al. 1996; Giordano et al. 2009; Farashi et al.
2015; Mehta et al. 2015; Clark et al. 2016). In this patient, the diagnosis of thalassemia inter-
media is in agreement with his clinical workup, including microcytic anemia and spleno-
megaly. Having determined the correct diagnosis of thalassemia intermedia in our patient
helped guide his clinical management, including decisions regarding indications for
Figure 2. Coverage differences in whole-exome sequencing revealed the possibility of an α-globin locus trip-
lication. (A) Plot of principal component analysis (PCA)-normalized z-scores of mean centered read coverages
across α-globin locus for 216 controls (gray) and case (red). Deviation from the control distribution of these
scores indicates the presence of a likely deletion or duplication. Multimapped reads were allowed given
the high homology between HBA1 and HBA2 in order to estimate the full length of the CNV event. (B) Plot
of PCA-normalized z-scores for specific bait targeting HBA1 exon 3.
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blood transfusion, monitoring and treating complications of chronic hemolysis and of iron
overload, periodic assessment for pulmonary hypertension, and consideration for treatment
with agents that induce fetal hemoglobin (Taher et al. 2013), as the increased production of
γ-globin improves the imbalance of the α- and β-globin chains (Musallam et al. 2013). Most
importantly, as a result of a definitive molecular diagnosis, we decided to not perform a
surgical splenectomy, which can ameliorate the severity of certain anemias (Lacy et al.
2016) but instead carries a high risk of postsplenectomy complications in thalassemia inter-
media patients (Karimi et al. 2011; Taher et al. 2013).
DISCUSSION
The clinical spectrum resulting from the combination of heterozygosity for β-thalassemia and
triplication of α-globin is wide and ranges from mild β-thalassemia minor to clinically signifi-
cant thalassemia intermedia (Kanavakis et al. 1983; Sampietro et al. 1983, Galanello et al.
1983, Thein et al. 1984; Henni et al. 1985, Camaschella et al. 1987; Kulozik et al. 1987;
Oron et al. 1994; Traeger-Synodinos et al. 1996; Bianco et al. 1997; Giordano et al. 2009;
Farashi et al. 2015; Mehta et al. 2015). Most commonly, the triplication of α-globin results
from abnormal homologous recombination, generating the common α−3.7 deletion and
the αααanti3.7 triplication. However, larger duplications, such as the one identified here,
have been described (Harteveld et al. 2008; Jiang et al. 2015; Clark et al. 2016). These larger
Figure 3. MLPA verifies a triplication of the whole α-globin cluster. (A) A schematic presentation of the α-glo-
bin locus including the genes involved in the triplication byMLPA studies. The black bar indicates the extent of
the triplication. (B) MLPA is a multiplex PCR method for detecting abnormal copy numbers. The y-axis repre-
sents the relative quantity of each amplicon. The black bar indicates the area of the triplication as diagnosed by
MLPA. The error bars refer to the standard deviation. The triplication begins upstream of the DNase I hyper-
sensitive site HS-40 (an upstream regulatory element ofHBA cluster genes) and ends downstream to theHBQ1
gene. ∗The reference genes (gray background) are located in other areas of the genome and serve as a vali-
dation of the technique in each run.
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triplications seem to uniformly result in more severe disease, at least as far as has been re-
ported in the literature, likely because they result in the addition of two extra α-globin copies,
contrasting with the αααanti3.7 triplication, which adds only one α-globin copy.
Importantly, these uncommon triplications are often missed by standard molecular tech-
nologies such as restriction endonuclease mapping and multiplex gap-PCR. Recently, three
duplications of the α-globin locus that extended well beyond the locus and would be unde-
tectable by standard approaches were identified by targeted genome sequencing (using a
unique library of DNA baits) in thalassemia intermedia patients with heterozygous mutations
in the β-globin gene (Clark et al. 2016). Here, we show that in addition to this approach and
targeted MLPA (Harteveld et al. 2008; Colosimo et al. 2011), standardWES can also be used
to identify extended α-globin CNVs. Thus, in certain cases whereWES has already been per-
formed, WES-based CNV calling provides a cost-effective approach for the identification of
copy-number changes across the α-globin locus.
Notably, the clinical and laboratory details of this patient initially suggested a diagnosis
of CDA, and the patient underwent a full genetic workup for all genes known to be involved
in these syndromes. In agreement with our own clinical experience as well as with other
recent studies, targeted or exome sequencing of clinical CDA cases occasionally results in
no genetic evidence of CDA but definitive evidence of alternative hematological disorders
explanative of the CDA-like phenotype (Roy et al. 2016). In these alternative disorders, stress
erythropoiesis potentially leads to the CDA-like phenotypes observed, but an accurate diag-
nosis can often have a significant impact on clinical decision-making in these cases.
WES-based CNV calling has successfully identified pathogenic variants in a number of
genetically unsolved cases. Variants identified are typically deletions, but here we show
that pathogenic increases in copy number can also be successfully identified in WES.
More generally, we suggest that WES-based CNV calling should be a standard part of any
WES pipeline and putative CNVs should be carefully investigated when standard variant
analyses are unrevealing prior to moving to more expensive approaches such as WGS.
METHODS
Peripheral blood and bone marrow samples were collected after informed consent was
obtained. Bone marrow aspiration smears were stained with Hematek (Siemens).
Sequencing and Analysis
DNA was extracted by DNA isolation kit from mammalian blood (Roche) according to the
manufacturer’s instructions. WES was performed as previously described with the exception
that Illumina ICE baits were used for DNA capture (Sankaran et al. 2012). Coverage across the
consensus codingDNA sequences (downloaded fromUCSCgenome browser onDecember
13, 2015) plus an additional 20 nt on each side of the exons was calculated using Picard tools
(Table 1). The variant call file was annotated with Variant Effect Predictor v83 (McLaren et al.
2016). The genome analysis toolkit (GATK) and Bcftools were then used to identify rare
variants (DePristo et al. 2011; Li 2011; Lek et al. 2016). No rare (defined as 0.01% allele
frequency in ExAC) damaging (missense or loss-of-function) mutations were present in the
patient in any of the known CDA or other red cell disorder genes (ANK1, SPTB, SPTA1,
SLC4A1, EPB42, EPB41, PIEZO1, KCNN4, GLUT1, G6PD, PKLR, NT5C3A, HK1, GPI,
PGK1, ALDOA, TPI1, PFKM, ALAS2, FECH, UROS, CDAN1, SEC23B, KIF23, KLF1,
GATA1, HBB, HBA1, HBA2, RPS19, RPL5, RPL11, RPL35A, RPS26, RPS24, RPS17, RPS7,
RPS10, RPL26, RPS29, RPS28, RPS27, RPL27, RPL15, RPL31, TSR2) with the exception of
IVS-I-110:G>A in HBB. Copy-number variant analysis was performed using XHMM
(Fromer et al. 2012). Controls were 216 unrelated cases from a Diamond–Blackfan anemia
α-Globin triplication identified by WES
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cohort that were sequenced at the Broad Institute at the same time as the case reported
here. Suggested XHMM parameters were used with the exception that CNVs were called
using both unique and multimapped exon read coverages (GATK DepthOfCoverage
parameters “–minMappingQuality 20” and “–minMappingQuality 0”, respectively), because
HBA1 and HBA2 are highly homologous.
Multiplex Ligation-Dependent Probe Amplification
MLPA was performed using the commercially available kit Salsa MLPA P140B HBA (MCR-
Holland) following the manufacturer’s instructions. The amplified fragments were separated
by capillary electrophoresis in the 3130XL Genetic Analyzer, ABI PRISM (Applied
Biosystems). Quantitative data were obtained with Gene-Mapper v3.7 software (Applied
Biosystems).
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